FDA's Yearly Germ Testing Guidelines Get Refreshed
Published Date: 5/12/2026
Notice
Summary
The FDA just dropped its yearly update on how it tests germs to see which medicines work best. This affects doctors, labs, and drug makers who rely on these test rules to fight infections smarter and faster. The updates keep everyone on the same page and help save time and money by improving treatment choices—comments on these changes are open now!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
Previous / Next Documents
Previous: 2026-09437 — Agency Information Collection Activities; Submission for OMB Review; Comment Request; Opportunity Zones Nomination Tool
The Treasury Department is updating its Opportunity Zones Nomination Tool, which helps states pick low-income areas for special tax breaks to encourage investment and job growth. They’re asking the public to comment by June 11, 2026, before sending the updated form for approval. This change keeps the program alive and kicking, making it easier for investors to support communities that need it most.
Next: 2026-09439 — Certain Ink Cartridges and Components Thereof II; Notice of a Commission Determination To Review in Part an Initial Determination Granting Complainants' Motion for Summary Determination of Violation; Request for Written Submissions on the Issues Under Review and on Remedy, the Public Interest, and Bonding
The U.S. International Trade Commission is taking a second look at a decision that found certain ink cartridges and parts violated Epson’s patents. They’re asking for written opinions on what should happen next, including possible fixes, public impact, and money matters. This affects companies importing or selling these ink cartridges and could lead to changes in what’s allowed or blocked soon.